SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is a major talking point as the community debates its unexpected resilience around the $69,000 level despite wider market and geopolitical uncertainty, while eagerly anticipating the impact of former President Trump's vocal push for crucial crypto legislation like the CLARITY Act.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending due to widespread community discussion around its resilience as a digital asset during ongoing geopolitical uncertainty and growing anticipation for clear crypto regulation via the Clarity Act, which many believe will unlock significant institutional adoption despite traditional banking resistance.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is experiencing extreme volatility amid surging crude oil prices driven by escalating Middle East tensions and concerns over the Strait of Hormuz. The community is fiercely debating whether the stock's recent sharp decline is due to market manipulation and dilution, or if it's a temporary shakeout before an anticipated explosive rally, drawing parallels to its history during past geopolitical events.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is aggressively trending, hitting multi-year highs on substantial volume, driven by community anticipation of imminent Phase 3 results for its groundbreaking AML drug, GPS, and widespread speculation of a substantial buyout or short squeeze.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is a focal point as investors await its earnings and presentations of new clinical data for ORLADEYO and the acquired navenibart at upcoming conferences. The community is actively debating the company's long-term growth and path to profitability against persistent high short interest and historical stock underperformance.

BlackRock Institutional Trust Company N.A. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

The iShares MSCI South Korea ETF (EWY) is trending due to a sharp market plunge, triggering circuit breakers, driven by escalating Middle East geopolitical tensions and surging energy prices. However, many in the community contend the panic is overblown, highlighting South Korea's diversified energy sources and long-term contracts, with the ETF's major tech holdings like Samsung and SK Hynix viewed as resilient due to strong AI-driven chip demand.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is a major discussion point after reporting robust revenue figures, projecting significant accelerated growth, and announcing a strategic partnership with TELUS for direct-to-device cellular broadband across Canada. The community is highly engaged, seeing these developments and an accelerating satellite launch cadence as strong validation of its commercial viability, with many anticipating a substantial shift from a "story stock" to an "infrastructure deployment" leader.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is trending following its transformative acquisition of Covelya Group, a move that significantly expands its subsea technology capabilities amid surging global demand for autonomous defense systems. The community is actively discussing the long-term bullish implications of this vertical integration and anticipated exchange uplistings, balancing enthusiasm with short-term considerations of share dilution.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is trending as strong earnings, an upbeat 2026 outlook, and a framework agreement to quadruple THAAD missile production coincide with escalating geopolitical tensions, fueling community discussion about a potential defense sector surge and increased procurement demand for its advanced systems.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is at the center of investor debate following concerns over its unannounced earnings date and a brief appearance on a U.S. military-linked companies list. Community sentiment is sharply divided, with bulls pointing to the recent Qwen AI model upgrade and oversold technicals, while bears cite ongoing geopolitical risks and margin pressures.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results

Xeris Biopharma (NASDAQ:XERS - Get Free Report) announced its quarterly earnings results on Monday. The company reported $0.06 earnings per share for the quarter, beating analysts' consensus...

Xeris Biopharma (NASDAQ:XERS) Receives Buy Rating from HC Wainwright

HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Xeris Biopharma in a research report on Monday...

Xeris Biopharma (NASDAQ:XERS) Shares Gap Up - Here's What Happened

Xeris Biopharma (NASDAQ:XERS) Shares Gap Up - What's Next...

Xeris Biopharma Q4 Earnings Call Highlights

Xeris Biopharma (NASDAQ:XERS) reported sharp top-line growth in the fourth quarter and full year 2025, highlighted by what management described as a defining milestone for the company: financial...

Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates

Xeris Biopharma (XERS) delivered earnings and revenue surprises of +84.62% and +5.38%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Xeris Biopharma Holdings Q4 Earnings Assessment

Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...

Xeris Biopharma (NASDAQ:XERS) Trading Down 8.3% - Should You Sell?

Xeris Biopharma (NASDAQ:XERS) Stock Price Down 8.3% - Should You Sell...

A Peek at Xeris Biopharma Holdings's Future Earnings

$XERS Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.07 up 333.33% YoY
• Reported revenue of $85.81M up 42.78% YoY
• Xeris expects full year 2026 total revenue to range from $375M to $390M, with gross margin improving modestly and Adjusted EBITDA increasing in total dollars compared to 2025.

Stocktwits

Xeris Biopharma Holdings Inc

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of $0.07 up 333.33% YoY
• Reported revenue of $85.81M up 42.78% YoY
• Xeris expects full year 2026 total revenue to range from $375M to $390M, with gross margin improving modestly and Adjusted EBITDA increasing in total dollars compared to 2025.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

$XERS Q4 &#39;25 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.07 up 333.33% YoY
• Reported revenue of $85.81M up 42.78% YoY
• Xeris expects full year 2026 total revenue between $375M and $390M, representing over 30% growth at the midpoint, with gross margin modestly improving and Adjusted EBITDA increasing in total dollars.

 Q4 '25 Earnings Results & Recap

• Reported GAAP EPS of $0.07 up 333.33% YoY
• Reported revenue of $85.81M up 42.78% YoY
• Xeris expects full year 2026 total revenue between $375M and $390M, representing over 30% growth at the midpoint, with gross margin modestly improving and Adjusted EBITDA increasing in total dollars.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

XERS
Xeris Biopharma Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Earnings Recap

Latest XERS News

XERSXeris Biopharma Holdings Inc